. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: Eur J Pharm Biopharm. 2020 Apr 23;151:189–198. doi: 10.1016/j.ejpb.2020.04.010

Table 2.

Minimum inhibitory concentration values after 12 h treatment with free linezolid or LIN-LPN

Bacterial strain	MIC50^** (μg/ml)		MIC90^** (μg/ml)
Bacterial strain	Free linezolid	LIN-LPN	Free linezolid	LIN-LPN
USA300-0114 (MRSA)	0.42±0.06	0.91±0.08	0.95±0.10	1.67±0.19
CDC-587 (MSSA)	0.64±0.04	1.38±0.11	1.41±0.15	1.89±0.22
*RP-62A (S. epidermidis)*	0.25±0.05	0.53±0.07	0.44±0.08	0.91±0.10

^**

MIC50 and MIC90 values were defined as the lowest concentration of linezolid (as free or encapsulated form) at which 90 and 50% of the isolates were inhibited, respectively. MRSA – methicillin-resistant S. aureus; MSSA – methicillin-sensitive S. aureus. All values expressed as mean±SD (n=3).